Group items tagged

Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

Developing a new medicine is a sophisticated and complex task which initially begins with the understanding of disease or condition as thoroughly as possible. At first, the researchers conduct studies in cells, tissues and animal models to determine whether the disease or condition can be influenced by new molecule.

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

Scottish biotechnology firm TC BioPharm (TCB) and Japanese immuno-cell therapy company Medinet have entered into a strategic collaboration to develop a new treatment for different types of cancer.

Patients with an inherited kidney disease may be helped by a drug that is currently available for other uses, scientists at UC Santa Barbara have discovered.